Tetridamina may be available in the countries listed below.
Tetridamina (DCIT) is also known as Tetridamine (Rec.INN)
International Drug Name Search
Glossary
| DCIT | Denominazione Comune Italiana |
| Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
Trimétazidine Torlan may be available in the countries listed below.
Trimetazidine dihydrochloride (a derivative of Trimetazidine) is reported as an ingredient of Trimétazidine Torlan in the following countries:
International Drug Name Search
Fem7 may be available in the countries listed below.
Estradiol is reported as an ingredient of Fem7 in the following countries:
Estradiol hemihydrate (a derivative of Estradiol) is reported as an ingredient of Fem7 in the following countries:
Levonorgestrel is reported as an ingredient of Fem7 in the following countries:
International Drug Name Search
Peritoneal Dialysis Solutions
With Attached stay•safe® Exchange Set
For Intraperitoneal Administration Only
89-905-65 Rev. 09/09
NO LATEX
DELFLEX® Neutral pH peritoneal dialysis solutions (supplied in standard, low magnesium and low magnesium/low calcium as 2 or 3 Liter product) are sterile, non-pyrogenic formulations of dextrose and electrolytes in water for injection, USP, for use in peritoneal dialysis. In comparison to conventional peritoneal dialysis solutions, DELFLEX® Neutral pH solutions are formulated to lower levels of glucose degradation products and provide a neutral pH of 7.0 ± 0.4, which is closer to the physiologic pH. The osmotic and buffer solutions are stored separately and mixed by the patient prior to use. The stay•safe® exchange set utilizes an easy to use dial designed to eliminate the use of clamps and to prevent touch contamination of internal connection components. Composition, calculated osmolarity, pH and ionic concentrations of the mixed solutions are shown in Table 2.
Hydrochloric acid and sodium hydroxide may be added for pH adjustment. The patient mixed solution pH is 7.0 ± 0.4.
Dextrose USP is chemically designated D-glucose monohydrate (C6H12O6 • H2O) a hexose sugar freely soluble in water. The structural formula is shown here:
These solutions do not contain antimicrobial agents or additional buffers. Exposure to temperatures above 25°C/77°F during transport and storage will lead to minor losses in moisture content. Higher temperatures lead to greater losses. It is unlikely that these minor losses will lead to clinically significant changes within the expiration period. Since the flexible inner bag is compounded from a specific polyvinyl chloride, water may permeate from the inner bag into the outerwrap in quantities insufficient to affect the solution significantly. Solutions in contact with the plastic inner bag can cause certain chemical components of the bag to leach out in very small amounts; however, the safety of the plastic formulation is supported by biological tests for plastic containers.
Nominal glucose degradation product (GDP) levels (immediately following sterilization) in DELFLEX®Neutral pH solution and DELFLEX® solution are reported in Table 1. The clinical relevance of these differences in GDP levels is unknown.
| Table 1. Glucose Degradation Product Levels* | ||
| Dextrose Concentration | DELFLEX® Neutral pH | DELFLEX® |
| *This is the sum (μmol/L) of the various component GDPs including: formaldehyde, acetaldehyde, furaldehyde, glyoxal, methylglyoxal, 5-hydroxymethylfurfural (5-HMF), and 3-deoxyglucosone (3DG). | ||
| 1.5% | 23 | 267 |
| 2.5% | 51 | 362 |
| 4.25% | 106 | 437 |
| Table 2. Composition, Calculated Osmolarity, pH, and Ionic Concentration | ||||||||||
| 2 Liter DELFLEX® Neutral pH | ||||||||||
| Standard Magnesium, Standard Calcium | Low Magnesium, Standard Calcium | Low Magnesium, Low Calcium | ||||||||
| 1.5% Dextrose | 2.5% Dextrose | 4.25% Dextrose | 1.5% Dextrose | 2.5% Dextrose | 4.25% Dextrose | 1.5% Dextrose | 2.5% Dextrose | 4.25% Dextrose | ||
| Main Bag Contents | ||||||||||
| Composition / 100ml | Dextrose Hydrous, USP (C6H12O6• H2O) | 1.52g | 2.56g | 4.36g | 1.54g | 2.56g | 4.36g | 1.54g | 2.56g | 4.36g |
| Sodium Chloride, USP (NaCl) | 581mg | 581 mg | 581mg | 552mg | 552 mg | 552 mg | 552 mg | 552 mg | 552 mg | |
| Calcium Chloride, USP (CaCl2• 2H2O) | 26.3mg | 26.3mg | 26.3mg | 26.3mg | 26.3mg | 26.3mg | 18.9mg | 18.9mg | 18.9mg | |
| Magnesium Chloride, USP (MgCl2 • 6H2O) | 15.6mg | 15.6mg | 15.6mg | 5.21mg | 5.21mg | 5.21mg | 5.21mg | 5.21mg | 5.21mg | |
| Mini-bag Contents | ||||||||||
| Sodium Lactate(C3H5NaO3) | 14.4mg | 14.4mg | 14.4mg | 16.7mg | 16.7mg | 16.7mg | 16.7mg | 16.7mg | 16.7mg | |
| Sodium Bicarbonate(NaHCO3) | 1.20g | 1.20g | 1.20g | 1.20g | 1.20g | 1.20g | 1.20g | 1.20g | 1.20g | |
| Total ingredient content AFTER mixing Main Bag and Mini-bag solutions | ||||||||||
| Dextrose Hydrous, USP (C6H12O6• H2O) | 1.5g | 2.5g | 4.25g | 1.5g | 2.5g | 4.25g | 1.5g | 2.5g | 4.25g | |
| Sodium Chloride, USP (NaCl) | 567mg | 567mg | 567mg | 538mg | 538mg | 538mg | 538mg | 538mg | 538mg | |
| Sodium Lactate(C3H5NaO3) | 353mg | 353mg | 353mg | 409mg | 409mg | 409mg | 409mg | 409mg | 409mg | |
| Sodium Bicarbonate(NaHCO3) | 29.4mg | 29.4mg | 29.4mg | 29.4mg | 29.4mg | 29.4mg | 29.4mg | 29.4mg | 29.4mg | |
| Calcium Chloride, USP (CaCl2• 2H2O) | 25.7 mg | 25.7 mg | 25.7 mg | 25.7 mg | 25.7 mg | 25.7 mg | 18.4 mg | 18.4 mg | 18.4 mg | |
| Magnesium Chloride, USP (MgCl2 • 6H2O) | 15.2 mg | 15.2 mg | 15.2 mg | 5.08 mg | 5.08 mg | 5.08 mg | 5.08 mg | 5.08 mg | 5.08 mg | |
| Osmolarity(mOsmoL/L)(calc) | 347 | 398 | 486 | 346 | 396 | 485 | 344 | 394 | 483 | |
| pH 7.0 ± 0.4 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | |
| Main Bag Contents | ||||||||||
| Ionic Composition(mEq/L) | Sodium | 99.4 | 99.4 | 99.4 | 94.3 | 94.3 | 94.3 | 94.3 | 94.3 | 94.3 |
| Calcium | 3.59 | 3.59 | 3.59 | 3.59 | 3.59 | 3.59 | 2.56 | 2.56 | 2.56 | |
| Magnesium | 1.54 | 1.54 | 1.54 | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 | |
| Chloride | 105 | 105 | 105 | 98.4 | 98.4 | 98.4 | 97.4 | 97.4 | 97.4 | |
| Mini-bag Contents | ||||||||||
| Sodium | 1428 | 1428 | 1428 | 1632 | 1632 | 1632 | 1632 | 1632 | 1632 | |
| Lactate | 1285 | 1285 | 1285 | 1489 | 1489 | 1489 | 1489 | 1489 | 1489 | |
| Bicarbonate | 143 | 143 | 143 | 143 | 143 | 143 | 143 | 143 | 143 | |
| Total ingredient content AFTER mixing Main Bag and Mini-bag solutions | ||||||||||
| Sodium | 132 | 132 | 132 | 132 | 132 | 132 | 132 | 132 | 132 | |
| Calcium | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 2.5 | 2.5 | |
| Magnesium | 1.5 | 1.5 | 1.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |
| Chloride | 102 | 102 | 102 | 96 | 96 | 96 | 95 | 95 | 95 | |
| Lactate | 31.5 | 31.5 | 31.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | |
| Bicarbonate | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | |
| 3 Liter DELFLEX® Neutral pH | ||||||||||
| Standard Magnesium, Standard Calcium | Low Magnesium, Standard Calcium | Low Magnesium, Low Calcium | ||||||||
| 1.5% Dextrose | 2.5% Dextrose | 4.25% Dextrose | 1.5% Dextrose | 2.5% Dextrose | 4.25% Dextrose | 1.5% Dextrose | 2.5% Dextrose | 4.25% Dextrose | ||
| Main Bag Contents | ||||||||||
| Composition / 100ml | Dextrose Hydrous, USP (C6H12O6• H2O) | 1.52 g | 2.54 g | 4.32g | 1.52g | 2.54 g | 4.32g | 1.52g | 2.54g | 4.32g |
| Sodium Chloride, USP (NaCl) | 576mg | 576 mg | 576 mg | 547mg | 547 mg | 547 mg | 547 mg | 547 mg | 547mg | |
| Calcium Chloride, USP (CaCl2• 2H2O) | 26.1mg | 26.1mg | 26.1mg | 26.1mg | 26.1mg | 26.1mg | 18.7mg | 18.7mg | 18.7mg | |
| Magnesium Chloride, USP (MgCl2 • 6H2O) | 15.4mg | 15.4mg | 15.4mg | 5.16mg | 5.16mg | 5.16mg | 5.16mg | 5.16mg | 5.16mg | |
| Mini-bag Contents | ||||||||||
| Sodium Lactate(C3H5NaO3) | 21.6 mg | 21.6mg | 21.6mg | 25.0mg | 25.0mg | 25.0 mg | 25.0mg | 25.0 mg | 25.0 mg | |
| Sodium Bicarbonate(NaHCO3) | 1.80 g | 1.80g | 1.80 g | 1.80g | 1.80g | 1.80g | 1.80g | 1.80g | 1.80g | |
| Total ingredient content AFTER mixing Main Bag and Mini-bag solutions | ||||||||||
| Dextrose Hydrous, USP (C6H12O6• H2O) | 1.5g | 2.5g | 4.25g | 1.5g | 2.5g | 4.25g | 1.5g | 2.5g | 4.25g | |
| Sodium Chloride, USP (NaCl) | 567mg | 567mg | 567mg | 538mg | 538mg | 538mg | 538mg | 538mg | 538mg | |
| Sodium Lactate(C3H5NaO3) | 353mg | 353mg | 353mg | 409mg | 409mg | 409mg | 409mg | 409mg | 409mg | |
| Sodium Bicarbonate(NaHCO3) | 29.4mg | 29.4mg | 29.4mg | 29.4mg | 29.4mg | 29.4mg | 29.4mg | 29.4mg | 29.4mg | |
| Calcium Chloride, USP (CaCl2• 2H2O) | 25.7 mg | 25.7 mg | 25.7 mg | 25.7 mg | 25.7 mg | 25.7 mg | 18.4 mg | 18.4 mg | 18.4 mg | |
| Magnesium Chloride, USP (MgCl2 • 6H2O) | 15.2 mg | 15.2 mg | 15.2 mg | 5.08 mg | 5.08 mg | 5.08 mg | 5.08 mg | 5.08 mg | 5.08 mg | |
| Osmolarity(mOsmoL/L)(calc) | 347 | 398 | 486 | 346 | 396 | 485 | 344 | 394 | 483 | |
| pH 7.0 ± 0.4 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | 7.0 | |
| Main Bag Contents | ||||||||||
| Ionic Composition(mEq/L) | Sodium | 98.6 | 98.6 | 98.6 | 93.5 | 93.5 | 93.5 | 93.5 | 93.5 | 93.5 |
| Calcium | 3.56 | 3.56 | 3.56 | 3.56 | 3.56 | 3.56 | 2.54 | 2.54 | 2.54 | |
| Magnesium | 1.52 | 1.52 | 1.52 | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 | 0.51 | |
| Chloride | 104 | 104 | 104 | 97.6 | 97.6 | 97.6 | 96.6 | 96.6 | 96.6 | |
| Mini-bag Contents | ||||||||||
| Sodium | 2142 | 2142 | 2142 | 2448 | 2448 | 2448 | 2448 | 2448 | 2448 | |
| Lactate | 1927 | 1927 | 1927 | 2233 | 2233 | 2233 | 2233 | 2233 | 2233 | |
| Bicarbonate | 214 | 214 | 214 | 214 | 214 | 214 | 214 | 214 | 214 | |
| Total ingredient content AFTER mixing Main Bag and Mini-bag solutions | ||||||||||
| Sodium | 132 | 132 | 132 | 132 | 132 | 132 | 132 | 132 | 132 | |
| Calcium | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 2.5 | 2.5 | 2.5 | |
| Magnesium | 1.5 | 1.5 | 1.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | |
| Chloride | 102 | 102 | 102 | 96 | 96 | 96 | 95 | 95 | 95 | |
| Lactate | 31.5 | 31.5 | 31.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | 36.5 | |
| Bicarbonate | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | |
Peritoneal dialysis is the process of filtering excess water and toxins from the bloodstream through a semi-permeable membrane. This process does not cure the disease, but prevents progression of symptoms. Dialysis for chronic kidney failure is essential to maintain life, unless the patient receives a kidney transplant. A peritoneal dialysis procedure utilizes the peritoneum (lining of the abdomen) as the semi-permeable membrane. The procedure is conducted by instilling peritoneal dialysis solution through a catheter in the abdomen into the peritoneal cavity. Since the peritoneum is heavily supplied with blood vessels, the contact of the solution with the peritoneum causes excess water and toxins in the bloodstream to be drawn across the membrane into the solution. This osmosis and diffusion occurs between the plasma of the patient and the peritoneal dialysis solution. After a period of time called “dwell time,” the solution is then drained from the patient.
This solution does not contain potassium. In situations in which there is a normal serum potassium level or hypokalemia, the addition of potassium chloride (up to a concentration of 4 mEq/L) may be indicated to prevent severe hypokalemia.
Addition of potassium chloride should be made after careful evaluation of serum and total body potassium and only under the direction of a physician.
Clinical studies have demonstrated that the use of low magnesium solutions resulted in significant increases in serum CO2 and decreases in serum magnesium levels. The decrease in magnesium levels did not cause clinically significant hypomagnesemia.
DELFLEX® peritoneal dialysis solutions are indicated in the treatment of chronic renal failure patients being maintained on peritoneal dialysis when nondialytic medical therapy is judged to be inadequate.
None Known
Not for Intravenous Injection.
Use Aseptic Technique.
It is important to mix the buffer (mini-bag) and main solutions thoroughly. Administer within 24 hours after mixing. Once buffer (mini-bag) and main solutions are mixed, medication may be added prior to administration.
Peritoneal dialysis should be done with great care in patients with a number of conditions, including disruption of the peritoneal membrane or diaphragm by surgery or trauma, extensive adhesions, bowel distention, undiagnosed abdominal disease, abdominal wall infection, hernias or burns, fecal fistula or colostomy, tense ascites, obesity, large polycystic kidneys, recent aortic graft replacement, lactic acidosis and severe pulmonary disease. When assessing peritoneal dialysis as the mode of therapy in such extreme situations, the benefits to the patient must be weighed against the possible complications.
Solutions containing lactate ion should be used with great care in patients with metabolic or respiratory alkalosis. Lactate should be administered with great care in those conditions in which there is an increased level or an impaired utilization of this ion, such as severe hepatic insufficiency.
An accurate fluid balance record must be kept and the weight of the patient carefully monitored to avoid over or under hydration with severe consequences, including congestive heart failure, volume depletion and shock.
Excessive use of DELFLEX® peritoneal dialysis solution with 4.25% dextrose during a peritoneal dialysis treatment can result in significant removal of water from the patient.
Stable patients undergoing maintenance peritoneal dialysis should have routine periodic evaluation of electrolyte blood chemistries and hematologic factors, as well as other indicators that determine the patient’s ongoing status.
After removing the outer wrap, check for minute leaks by squeezing the container firmly. If leaks are found, discard the solution because the sterility may be impaired. (A small amount of moisture may be present inside the overwrap, which is normal condensation from the sterilization process).
Serum calcium levels in patients using low calcium concentrations should be monitored and if found to be low, the peritoneal solution in use should be altered to one with a higher calcium concentration.
General:
Administer only if the solution is clear, all seals are intact, and there is no evidence of leaking.
It is important to mix the buffer (mini-bag) and main solutions thoroughly. Administer within 24 hours after mixing. Once buffer and main solutions are mixed, medication may be added prior to administration.
Do Not Heat In A Microwave Oven
Care should be taken to see that the catheter is inserted completely, since leakage around the catheter, if not controlled, can create edema from subcutaneous infiltration of the dialysis solution. This will also create an inaccurate fluid balance measurement.
DELFLEX® Peritoneal Dialysis solutions do not include potassium. Potassium chloride should only be added under the direction of a physician after careful evaluation of both serum and total body potassium.
The overwrap must be removed immediately before use and is provided with a “Tear Open” feature to make removal easy. See instructions in Directions for Use section.
Disconnect from disk only when knob is in position 4 (••••).
Aseptic technique must be used throughout the procedure and at its termination in order to reduce the possibility of infection.
Significant loss of protein, amino acids and water soluble vitamins may occur during peritoneal dialysis. Replacement therapy should be provided as necessary.
Serum electrolytes, magnesium, bicarbonate levels and fluid balance should be periodically monitored.
Long term animal studies with DELFLEX® peritoneal dialysis solutions have not been performed to evaluate the carcinogenic potential, mutagenic potential or effect on fertility.
Pregnancy Category C. Animal reproduction studies have not been conducted with DELFLEX peritoneal dialysis solutions. It is also not known whether DELFLEX peritoneal dialysis solutions can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. DELFLEX peritoneal dialysis solutions should be given to a pregnant woman only if clearly needed.
Caution should be exercised when DELFLEX peritoneal dialysis solutions are administered to a nursing woman.
Safety and effectiveness in pediatric patients have not been established.
Adverse reactions to peritoneal dialysis include mechanical and solution related problems as well as the results of contamination of equipment or improper technique in catheter placement. Abdominal pain, bleeding, peritonitis, subcutaneous infection around a peritoneal catheter, catheter blockage, difficulty in fluid removal, and ileus are among the complications of the procedure. Solution related adverse reactions might include peritonitis, catheter site infection, electrolyte and fluid imbalances, hypovolemia, hypervolemia, hypertension, hypotension, disequilibrium syndrome and muscle cramping.
If an adverse reaction does occur, institute appropriate therapeutic procedures according to the patient’s needs and conditions, and save the remainder of the fluid in the bag for evaluation if deemed necessary.
DELFLEX peritoneal dialysis solutions are provided for intraperitoneal administration only. The mode of therapy, frequency of treatment, formulation, exchange volume, duration of dwell, and length of dialysis should be selected by the physician responsible for the treatment of the individual patient.
To avoid the risk of severe dehydration or hypovolemia and to minimize the loss of protein, it is advisable to select the peritoneal dialysis solution with lowest level of osmolarity consistent with the fluid removal requirements for that exchange.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Additives may be incompatible. Do not store solutions containing additives.
For administration see Directions for Use section.
DELFLEX peritoneal dialysis solutions are delivered in single-dose flexible bags. All DELFLEX peritoneal dialysis solutions have overfills declared on the container label. The flexible containers have the capacity for drainage in excess of their stated fill volume for ultrafiltration from the patient.
DELFLEX peritoneal dialysis solutions with an attached stay•safe® exchange set are available in containers as shown in the Table 2 in the Description section.
Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F). See USP Controlled Room Temperature. Brief exposure to temperatures up to 40°C/104°F may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F).
Keep DELFLEX and all medicines out of the reach of children.
Fresenius Medical Care North America
920 Winter Street
Waltham, MA 02451
1-800-323-5188
Patent Pending
Revised 09/09
| Not for Intravenous Injection. Do not microwave. |
| Warm solution as directed by your healthcare provider. |
Directions for Use
Get Ready
Clean work surface. Use aseptic technique.
Gather supplies:
Warmed Delflex Neutral pH Peritoneal Dialysis bag with the attached stay•safe Exchange Set.
Povidone iodine prefilled stay•safe cap, a stand alone item provided separately.
stay•safe® organizer, a stand alone item provided separately (Optional; FMCNA recommends its use)
Prescribed medicine(s) if ordered by your healthcare provider
Mask
See Figure A for identification of each item described above.
Put on the mask. Wash your hands.
Clamp the Extension Tube Set coming from the catheter.
Tear the overwrap across from the slit edge to open. Wipe away any moisture from the solution bags.
Inspect DEFLEX Solution Bags:
Place the DEFLEX Solution on the work surface. See Figure B.
Position solution bags and drain bag as shown in Figure C.
Squeeze the main bag and the mini bag to check for leaks. When squeezing the mini-bag, the bag should remain firm. No solution should leak into the main bag or into the drain line.
| Do not use Delflex Neutral pH Solution Set if: |
| • Leaks are found |
| • The solution bags are damaged |
| • Solution is cloudy or discolored |
| • Red or blue cone is broken |
| Throw away Delflex Neutral pH Solution set and notify your healthcare provider. |
Turn the blue position indicator on the stay•safe® disc counter-clockwise until it fits into thecut-out portion of the colored plastic cover on the disc as illustrated in Figure D. This will allow the effluent in your peritoneal cavity to drain. Remove the plastic cover while the indicator is in this position (Position1: •). Once the cover is removed, do not turn counter-clockwise.
Mix Delflex® Neutral pH Solution
Important: Mix the mini-bag and main solutions thoroughly. Use the solution within 24 hours after mixing.
With the solution bags stretched out on the work surface, break the red cone by bending. See Figure E.
Fold the min-bag in half. Squeeze the solution from the mini-bag into the main solution bag by pressing the two halves together until the mini-bag is empty. See Figure F(Step 1).
Push down on main solution bag to flush solution back into the mini-bag. Completely refill mini-bag with solution. See Figure F (Step 2).
Repeat steps 2 and 3 above to make sure that all of the contents of the mini-bag have been completely flushed into the main solution bag.
Grab the tubing at the bottom of the main solution bag. While keeping the top portion of the bag on the table, flip the bag lengthwise using a back and forth motion to mix solutions. See Figure G. Repeat this step to mix solutions.
Fold mini-bag in half and squeeze it until there is no solution left. Slide folded mini-bag into the slit of the white cover to show the blue cone. See Figure H.
The solution is now ready for use.
Administer Peritoneal Dialysis Solution
If adding medicine(s):
Clean the medication port as instructed by your healthcare provider.
Add the medicine(s).
Turn the bag upside down several times to mix the medicine.
Hang the solution bag from the I.V. pole. Place the drain bag at floor level.
Break the blue cone on the bottom of the mini-bag. See Figure I. (if using the Organizer, place the stay•safe® disc in the organizer as shown in Figure J)
Remove the new stay•safe® cap from its package. The new stay•safe® cap is the stand alone item
Mucobrol may be available in the countries listed below.
Bromhexine hydrochloride (a derivative of Bromhexine) is reported as an ingredient of Mucobrol in the following countries:
International Drug Name Search
Timentin is a brand name of clavulanate/ticarcillin, approved by the FDA in the following formulation(s):
No. There is currently no therapeutically equivalent version of Timentin available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Timentin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
There are no current U.S. patents associated with Timentin.
Irinotesin may be available in the countries listed below.
Irinotecan hydrochloride trihydrate (a derivative of Irinotecan) is reported as an ingredient of Irinotesin in the following countries:
International Drug Name Search
Bioarginina may be available in the countries listed below.
Arginine is reported as an ingredient of Bioarginina in the following countries:
Arginine hydrochloride (a derivative of Arginine) is reported as an ingredient of Bioarginina in the following countries:
International Drug Name Search
Bacitracin zinc salt (a derivative of Bacitracin) is reported as an ingredient of Double Antibiotic Ointment in the following countries:
Polymyxin B sulfate (a derivative of Polymyxin B) is reported as an ingredient of Double Antibiotic Ointment in the following countries:
International Drug Name Search
Coffo-Selt may be available in the countries listed below.
Caffeine is reported as an ingredient of Coffo-Selt in the following countries:
Phenazone is reported as an ingredient of Coffo-Selt in the following countries:
International Drug Name Search
Vectoryl may be available in the countries listed below.
Perindopril erbumine (a derivative of Perindopril) is reported as an ingredient of Vectoryl in the following countries:
International Drug Name Search
